Investment Rating - The report maintains an investment rating of "Outperform the Market" for the pharmaceutical and biotechnology industry [5]. Core Insights - The report emphasizes the importance of innovation, international expansion, and the aging economy in the pharmaceutical and biotechnology sectors [5]. Medical Devices - The global medical device market was valued at $684.3 billion in 2023 and is expected to reach $766.7 billion by 2025, with a compound annual growth rate (CAGR) of 5.9% [1][12]. - The proportion of Chinese medical device companies in the global revenue TOP100 increased from 14% in 2010 to 18% in 2023, indicating a growing presence in the global market [21] [20]. - The export of medical devices is transitioning from low-value consumables to mid-to-high-end devices such as CT, MRI, ultrasound, and in vitro diagnostics [1][28]. Pharmaceuticals - High-quality innovation is becoming the main theme in the development of domestic pharmaceuticals, with 40 innovative drug licensing deals in 2023-2024, seven of which received over $150 million in upfront payments [2]. - The introduction of supportive policies for innovative drug development reflects the government's encouragement for high-quality innovation [2]. - The surplus in medical insurance funds provides a guarantee for increasing the proportion of innovative drug reimbursements [2]. Retail Pharmacies - The retail pharmacy sector is expected to benefit from the ongoing prescription outflow, with sales increasing from 337.5 billion yuan in 2016 to 553.3 billion yuan in 2023, and the terminal market share rising from 22.5% to 29.3% [3]. - The concentration of the retail pharmacy industry is anticipated to increase as leading pharmacies expand through self-built stores, acquisitions, and franchises [3]. Traditional Chinese Medicine (TCM) - The aging population, which accounted for 15.4% of the population in 2023, is expected to drive demand for health management, benefiting TCM [4]. - The price of Chinese medicinal materials increased by 17.4% year-on-year by the end of 2023, with an 8.51% increase from early 2024 to May, suggesting potential for price increases in TCM OTC products [4]. Investment Recommendations - For the medical device sector, the report recommends focusing on leading companies in various sub-sectors, such as Mindray Medical, Yuyue Medical, and Huaitai Medical [5]. - In the pharmaceutical sector, it suggests looking at high-quality innovative drugs with "First-in-Class" (FIC) or "Best-in-Class" (BIC) potential, recommending companies like Heng Rui Medicine, Kangfang Biotech, and Innovent Biologics [5]. - For TCM, it highlights leading OTC brands that benefit from the aging trend, recommending China Resources Sanjiu and Dong-E E-Jiao [5]. - In the retail pharmacy sector, it advises focusing on compliant and large-scale leading enterprises, particularly Yifeng Pharmacy, while also suggesting attention to other players like Lao Baixing, Dazhonglin, Yixin Tang, and Jianzhijia [5].

Investment Rating - The report maintains an investment rating of "Outperform the Market" for the express delivery sector [5]. Core Insights - The express delivery industry is experiencing sustained high demand, with a significant year-on-year growth in business volume. The total express delivery volume reached 14.78 billion pieces in May, representing a year-on-year increase of 23.8% [2][12]. - The average single ticket price in the industry has seen a controlled decline, with a month-on-month decrease of 1.78% in May. The overall price competition remains manageable despite some fluctuations [3][22]. - The market concentration has slightly increased, with the CR8 index rising to 85.2 in May, indicating a stable market share among leading express delivery brands [4][33]. Summary by Sections 1. Business Volume: Sustained High Demand - The retail sales in May reached 3.92 trillion yuan, with a year-on-year growth of 3.7%, and the online shopping penetration rate increased to 24.7% [12]. - The express delivery volume for May was 14.78 billion pieces, showing a year-on-year growth of 23.8% and a month-on-month increase of 1.1% [2][12]. - Leading express brands have outperformed the industry growth rate, with significant increases in their respective volumes [17]. 2. Single Ticket Price: Seasonal Price Fluctuations - The average single ticket price in May was 7.85 yuan, reflecting a year-on-year decrease of 12.21% and a month-on-month decline of 1.78% [22]. - Price strategies among express companies show significant differentiation, with intense competition in low-price segments [27][31]. 3. Industry Structure: Slight Increase in Concentration - The CR8 index for express delivery brands increased to 85.2 in May, indicating a slight rise in market concentration compared to April [4][34]. - The market shares of leading companies remain stable, with SF Express, YTO Express, Yunda Express, and Shentong Express holding shares of 7.58%, 15.45%, 13.81%, and 13.16% respectively [4][37]. 4. Investment Recommendations: Profitability Potential - With the expected increase in business volume and manageable price competition, the report suggests focusing on leading companies with stable profitability in the express delivery sector [5][39].

Investment Rating - The investment recommendation for the industry is "Outperform the Market" (maintained) [5]. Core Insights - The potential production capacity of allulose is expected to increase significantly, reaching 128,000 tons, compared to the current capacity of 15,000 tons, indicating an increase of over eight times. This is attributed to allulose's advantages such as good sugar reduction functionality, similar taste to sucrose, natural without side effects, and anti-inflammatory properties that regulate blood sugar levels [2][12]. - The domestic market for allulose is anticipated to open quickly once it receives approval from the National Health Commission (NHC). The approval process has accelerated recently, and if granted within the next two years, companies that have positioned themselves early in the allulose market are likely to benefit significantly [3][17]. - Internationally, establishing production facilities overseas presents another strategic opportunity for allulose companies. The U.S. FDA has approved allulose as a food additive, and companies that set up production bases abroad can benefit from tariff advantages and increased orders due to supply chain optimization [4][19]. Summary by Sections 1. Industry Opportunities for Allulose - Allulose is recognized as a healthy natural sugar substitute, with a growing market driven by aging populations. It serves as a better alternative to sucrose and erythritol [9][10]. - The domestic market for allulose is expected to open rapidly due to its favorable properties, with significant replacement potential in the sugar market, which is estimated at 15.5 million tons in 2023 [15][17]. 2. Investment Recommendations - Attention should be paid to the progress of allulose's approval as a new food ingredient, as this will benefit the entire industry [22][23]. - Companies that are establishing overseas production bases for allulose should be prioritized, especially those that are the first to do so, as they are likely to gain significant tariff reductions and order advantages [24].

Investment Rating - The report maintains an "Outperform" rating for the textile and apparel industry [7] Core Insights - Functional apparel is experiencing structural growth potential, with a focus on sun protection clothing as summer approaches [1][11] - The narrow (national standard) sun protection clothing market has reached approximately 100 billion yuan, with growth rates expected to slow due to market saturation [2][17] - Brand competition is intensifying, with significant market players like JiaoXia and JiaoNei leading in market share, while fashion appeal becomes a key competitive factor [3][23] Summary by Sections Functional Apparel Market - The functional apparel market shows potential for growth, with a notable rise in demand for sun protection clothing during extreme heat conditions [1][15] - The market for sun protection clothing is projected to maintain rapid growth in 2024, despite a slowdown in growth rates compared to previous years [2][19] Development Stage - The sun protection clothing market has reached a scale of around 100 billion yuan, with online sales showing a significant increase [2][17] - The market is entering a phase of brand consolidation, with a decrease in the number of market participants and an increase in mid-to-high-end branded products [2][21] Brand Competition - JiaoXia holds a significant market share, particularly in the mid-to-high-end price range, with intense competition among various brands [3][23] - The focus of brand competition has shifted towards product comfort and design, alongside aggressive marketing strategies involving celebrity endorsements [3][24] Leading Companies - JiaoXia has expanded its product range and channels, achieving substantial sales growth in sun protection clothing, with 2021 revenues reaching 710 million yuan [4][21] - Bosideng is also making strides in the sun protection clothing segment, enhancing its product offerings and marketing efforts to align with fashion trends [5][24]

Summary of Conference Call Company or Industry Involved - The conference call is associated with Guolian Securities Research Institute, focusing on investment management and advisory services. Core Points and Arguments - The call is intended solely for clients on the whitelist of Guolian Securities Research Institute, emphasizing the exclusivity of the information shared [1] - It is clearly stated that the meeting does not constitute investment advice, and participants are responsible for their own investment decisions and risks [1] - Guolian Securities disclaims any liability for losses incurred by participants due to the use of the meeting content [1] Other Important but Possibly Overlooked Content - The call highlights the importance of self-reliance in investment decisions, indicating a focus on investor education and risk awareness [1]

Summary of Conference Call Company/Industry Involved - The conference call pertains to Guolian Securities, specifically focusing on its research department and investor suitability management practices [1] Core Points and Arguments - The call is intended exclusively for Guolian Securities' whitelist clients, indicating a selective approach to information dissemination [1] - It is emphasized that the content of the meeting does not constitute investment advice, highlighting the importance of independent decision-making by participants [1] - Participants are reminded that they bear the responsibility for their investment decisions and associated risks, which underscores the company's stance on risk management [1] - Guolian Securities disclaims any liability for losses incurred by participants due to the use of the meeting content, reinforcing the need for personal accountability [1] Other Important but Possibly Overlooked Content - The call serves as a reminder of the regulatory framework surrounding investor suitability, which is crucial for maintaining compliance in the financial services industry [1] - The focus on a whitelist client base may indicate a strategic effort to enhance client relationships and provide tailored insights to a select group [1]

Fund Performance and Trends - Active funds have underperformed the CSI 800 index, with negative fund inflows indicating a shift towards passive and bond funds[8] - The large-cap value style has shown strong performance with a year-to-date increase of 7%, while the large-cap balanced style gained 2.5%[9] - Active equity funds have increased their holdings in low PE stocks (below 20) to over 30% of their market cap, while reducing exposure to high PE stocks (above 50)[10] Fund Issuance and Market Dynamics - The issuance of rights funds remains low, with passive index and enhanced index funds receiving positive net subscriptions[25] - As of May 2024, the share of rights fund issuance has decreased by 8.12 percentage points compared to the entire year of 2023, now accounting for 19.24%[26] - Bond funds have been favored, with short-term bond funds being more popular than medium to long-term bond funds[25] Investment Strategies and Recommendations - The report suggests focusing on balanced allocation and funds with alpha generation capabilities due to rapid market style rotations[10] - For balanced active funds, emphasis is placed on industry balance and alpha generation ability, evaluated through excess returns and stock selection capabilities[11] - Enhanced index funds should be assessed based on win rates, stability, and average excess returns, with some enhanced index funds meeting criteria for large-cap and balanced investments[12]

Investment Rating - The report maintains an "Outperform" rating for the electronic sector [2]. Core Insights - Bumping technology is a crucial foundation for advanced packaging, enabling various advanced packaging structures and processes [3][9]. - The global advanced packaging chip shipment volume was 58.1 billion units in 2022, expected to reach 78.1 billion units by 2027, with a CAGR of 4.9% [4][17]. - The shipment volume of flip chip (FC) is projected to grow from 14 billion units in 2022 (24% of total advanced packaging) to 21.9 billion units by 2027 (28% of total), with a CAGR of 8.4% [4][17]. - The rapid growth of Bumping technology is anticipated to create significant investment opportunities in equipment [5][30]. Summary by Sections 1. Bumping Market Development - Bumping is a key technology in advanced packaging, differentiating itself from traditional packaging methods by using flip chip bonding [9]. - The domestic Bumping market has substantial growth potential, with advanced packaging technologies expected to penetrate various sectors such as mobile, automotive, and data centers [15][17]. - The advanced packaging market is primarily dominated by foreign players, indicating significant growth opportunities for domestic companies [22]. 2. Investment Recommendations - The report suggests focusing on the advanced packaging equipment and materials supply chain, highlighting companies like ChipSource, Shengmei Shanghai, and Huahai Qingke [6][30]. - It also recommends monitoring the semiconductor recovery cycle, particularly in AI hardware products, which are expected to drive growth in consumer electronics [31]. 3. Equipment Investment Opportunities - The demand for advanced packaging equipment is expected to rise due to the increasing complexity of Bumping processes, which require higher precision and performance [5][24]. - Domestic manufacturers are making significant progress in producing equipment for Bumping processes, including photolithography and PVD equipment [29].

Investment Rating - Investment recommendation: Outperform the market (maintained) [2] Core Insights - Bumping is a core technology for advanced packaging, enabling various advanced packaging structures and processes [3][9] - The global advanced packaging chip shipment volume was 58.1 billion units in 2022, expected to reach 78.1 billion units by 2027, with a CAGR of 4.9% [4][22] - The shipment volume of Flip-Chip (FC) is projected to grow from 14 billion units in 2022 to 21.9 billion units by 2027, with a CAGR of 8.4%, indicating a faster growth rate than the overall advanced packaging chip shipment [4][22] - The rapid development of Bumping technology is expected to create investment opportunities in equipment [5][30] Summary by Sections 1. Bumping Market Development - Bumping is a key technology in advanced packaging, differentiating itself from traditional packaging methods by using flip-chip bonding for electrical connections [3][9] - The domestic Bumping market has significant potential, with China’s advanced packaging market share lagging behind the global market [18][22] 2. Investment Recommendations - Focus on the advanced packaging equipment and materials supply chain, with recommended companies including ChipSource, Shengmei Shanghai, Huahai Qingke, and others [6][30] - Attention should also be given to the semiconductor recovery cycle, with potential growth in AI hardware products driving demand [6][31]

2024 年 06 月 21 日 内容摘要 从需求端来看，制造业企业固定资产投资近两年显著走强（4 月累计同比： 9.7%）。有市场观点认为这与微观体感存在差异，我们用 1541 家 2016 年前 上市的制造业企业的数据和统计局的固定资产投资数据进行了交叉验证。 结果显示，统计局公布的固定资产投资数据具有较好的代表性（拟合优度 0.88），企业资本开支的确在近两年明显走强。从供给端来看，与企业资本 开支最为相关的装备制造业的工业增加值也表现强劲(2023 年同比 6.8%)。 新周期的量与价 为何物价水平仍表现偏弱？参考旧金山联储的方法，我们发现 2023 年 Q2 以来，供给的扩张可能抑制了 CPI 的回升：对 4 个季度 CPI 的 8 个主要分 项的分析显示，价格低于趋势水平的情况略超出一半（18/32），同时，大 部分情况下，消费量都高于趋势水平（26/32）。供给的扩张意味着潜在经 济增速和自然利率的回升，价格低迷或只是阶段性现象。展望未来，我们 预计伴随着经济的温和复苏，物价水平或也将有所回升。 相关报告 1、《近期黄金上涨之"谜"：——宏观深度报告》 2024.04.26 2、《美国小银行的大 ...